Aod-9604 dosage

The only publicly reported human dosing data for AOD-9604 comes from a single Phase II obesity trial that dosed participants at 1 mg subcutaneously per day for 12 weeks. That trial showed modest fat loss with minimal adverse events, but the compound was never advanced to Phase III, never approved by any regulatory authority, and the sponsoring company eventually abandoned clinical development. No large-scale controlled studies have replicated the findings, and no dose-response relationship has been established in humans.

The Fragment That Was Supposed to Separate Fat Loss from Growth

AOD-9604 is a 16-amino-acid synthetic peptide derived from positions 177–191 of the C-terminal region of human growth hormone (hGH), with an additional tyrosine residue attached at the N-terminus to improve stability. It was developed in the late 1990s by Metabolic Pharmaceuticals Ltd. (Australia) after researchers identified this region as responsible for hGH's lipolytic activity. The intention was to isolate the fat-mobilizing effects of hGH without triggering the insulin resistance, acromegalic changes, or muscle growth that come with full-length hormone administration.

The peptide's molecular weight is approximately 1815 Da. Unlike intact hGH, AOD-9604 does not bind to the growth hormone receptor (GHR). This structural distinction was the entire rationale for its development: it was meant to bypass the JAK2-STAT5 signaling cascade and avoid stimulating hepatic IGF-1 production, which drives both anabolic growth and metabolic side effects.

Whether this theoretical separation holds up in practice remains contested. The peptide did complete Phase II trials, but its failure to advance and the lack of independent replication leave the mechanism less validated than the marketing materials suggest.

Lipolysis Without Growth Hormone Receptor Binding

AOD-9604 appears to stimulate lipolysis through mechanisms that do not involve the canonical GHR pathway. In adipocyte culture models, the peptide increased glycerol release—a marker of fat breakdown—without activating STAT5 phosphorylation, which is the hallmark of GHR signaling. Instead, researchers have proposed that AOD-9604 acts directly on beta-adrenergic receptors or influences intracellular lipolytic pathways downstream of receptor activation, though the precise molecular target remains incompletely characterized.

In rodent studies, AOD-9604 administration increased fat oxidation and reduced adipose tissue accumulation without elevating serum IGF-1 levels. This dissociation from the GHR-IGF-1 axis theoretically explains why the peptide did not produce the hyperglycemia or soft tissue growth seen with exogenous hGH. However, these effects were dose-dependent and modest in magnitude, and not all studies demonstrated statistically significant reductions in body fat mass when corrected for food intake.

More recent preclinical work has also identified non-lipolytic activity. In cartilage repair models using rabbit knees, AOD-9604 appeared to promote chondrocyte proliferation and matrix synthesis through pathways involving transforming growth factor-beta (TGF-β). This finding was unexpected given the peptide's design, and it suggests that the C-terminal fragment of hGH may have pleiotropic effects beyond fat metabolism. Whether these effects occur at physiologically relevant concentrations in humans is unknown.

One Phase II Trial, No Follow-Up, and a Clinical Development Dead End

The primary human evidence for AOD-9604 comes from a 12-week randomized controlled trial conducted by Metabolic Pharmaceuticals and published in 2004. The study enrolled 300 obese adults (BMI 30–40 kg/m²) and assigned them to receive either placebo or one of several doses of subcutaneous AOD-9604 ranging from 0.5 mg to 2 mg daily. The highest-performing group received 1 mg per day.

At the end of the study, participants in the 1 mg group lost an average of 2.6 kg more than placebo, with most of the difference attributed to fat mass rather than lean tissue. The treatment was generally well tolerated, with injection-site reactions being the most common adverse event. Importantly, glucose tolerance and insulin sensitivity did not worsen—a key distinction from full-length hGH.

Despite these results, AOD-9604 was never brought to market. The FDA declined to approve it in 2007, citing concerns about efficacy (the magnitude of weight loss was modest) and the lack of long-term data. Metabolic Pharmaceuticals did not pursue further trials, and the compound has remained in regulatory limbo ever since. No independent research groups have published replication studies in humans, and no subsequent trials have tested higher doses, longer durations, or combination protocols.

This leaves the evidence base for human use thin and incomplete. The single Phase II trial provides proof of concept, but it does not establish optimal dosing, long-term safety, or clinical utility compared to other interventions. For research purposes only, AOD-9604 remains a molecule with suggestive but unvalidated effects.

Dosing, Half-Life, and Administration in Published Research

The 1 mg subcutaneous daily dose used in the Phase II trial is the only human dose backed by controlled data. Lower doses (0.5 mg) showed weaker effects, and higher doses (2 mg) did not produce substantially greater fat loss. The trial administered the peptide once per day, typically in the morning, and participants were counseled to follow a mild caloric restriction diet concurrently.

Pharmacokinetic studies in rodents suggest that AOD-9604 has a relatively short half-life, estimated at 30–60 minutes following subcutaneous injection. This rapid clearance means that sustained effects likely depend on repeated dosing rather than prolonged receptor occupancy. Whether twice-daily dosing would improve efficacy in humans has not been tested.

Subcutaneous administration is standard. There are no published studies testing oral bioavailability, and the peptide is assumed to be degraded in the gastrointestinal tract like most unprotected peptides. Stability data indicate that lyophilized AOD-9604 remains stable at -20°C for at least one year, but reconstituted solutions should be refrigerated and used within several weeks to minimize degradation.

No formal drug interaction studies have been conducted. Because AOD-9604 does not appear to influence insulin signaling or thyroid function in the available data, the risk of metabolic drug interactions seems low, but this remains speculative in the absence of controlled testing.

FAQ

Q: Is 1 mg per day the standard dose for AOD-9604?

It is the only dose tested in a controlled human trial. That trial showed modest fat loss over 12 weeks with good tolerability, but the compound was never approved, and no follow-up studies have tested whether higher or more frequent dosing improves outcomes.

Q: Does AOD-9604 require a prescription or medical supervision?

AOD-9604 is not approved for human use by the FDA, EMA, or any major regulatory body. It is legally available only for research purposes. Any human use outside of formal clinical trials occurs without regulatory oversight and without validated safety or efficacy data.

Q: How does AOD-9604 compare to other fat-loss peptides like CJC-1295?

CJC-1295 stimulates endogenous growth hormone release, which increases IGF-1 and may promote both fat loss and lean tissue growth. AOD-9604 was designed to avoid GH receptor activation entirely, which theoretically limits anabolic effects and metabolic side effects. However, CJC-1295 has more published human data, while AOD-9604 has a single trial and no regulatory approval.

Q: Can AOD-9604 be used for cartilage repair?

Animal studies in rabbits showed that AOD-9604 promoted cartilage regeneration in osteoarthritis models, possibly through TGF-β signaling. No human trials have tested this application, and the doses used in cartilage studies were higher than those used for fat loss. The mechanism is poorly understood and independent replication is lacking.

Q: What are the known risks of using AOD-9604?

The Phase II trial reported mild injection-site reactions and no serious adverse events over 12 weeks. Long-term safety data do not exist. Because the peptide was never formally approved, post-market surveillance has never occurred, and rare or delayed risks remain uncharacterized.

This article is for informational and research purposes only. AOD-9604 is not approved for human use and should not be used outside of controlled research settings. Consult a licensed healthcare provider before considering any investigational compound.